Search Within

Randy Yeh

Formats
  1. Journal Article (29)
  2. Review (22)
  3. Meeting Abstract (17)
  4. Correspondence (2)
  5. Editorial (2)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Molecular Imaging and Therapy Service (75)
  2. Radiology, Department of (75)
  3. Department of Medicine (26)
  4. Body Imaging Service (25)
  5. Solid Tumor Oncology Division (25)
  6. Epidemiology and Biostatistics (22)

More Groups

People
  1. Jeeban Das (15)
  2. Michael Berger (7)
  3. Abraham Wu (6)
  4. Charles Rudin (6)
  5. Constantinos Sofocleous (6)
  6. Geoffrey Ku (6)

More People

Years
  1. 2025 (9)
  2. 2024 (11)
  3. 2023 (17)
  4. 2022 (14)
  5. 2021 (13)
  6. 2020 (8)

More Years

Publications
  1. Journal of Nuclear Medicine (11)
  2. Journal of Clinical Oncology (7)
  3. Radiology (6)
  4. Cancers (4)
  5. European Journal of Nuclear Medicine and Molecular Imaging (4)
  6. American Journal of Neuroradiology (3)

More Publications

Publishers
  1. MDPI (11)
  2. Society of Nuclear Medicine (11)
  3. American Society of Clinical Oncology (8)
  4. Elsevier Inc. (8)
  5. Springer (8)
  6. Elsevier Science, Inc. (5)

More Publishers

Results (75)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Standardized reporting of oncologic functional response: Oncologic response lexicon for PET/CT
    Meeting Abstract

    Wray, R.; Do, R.; Schoder, H.; Yeh, R.; Mayerhoefer, M.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Multimodal large language model based PET/CT report generation: Capabilities and comparison of ChatGPT-4 versus ChatGPT-3.5
    Meeting Abstract

    Wray, R.; Yeh, R.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Development of (18)F-fluoromisonidazole hypoxia PET/CT diagnostic interpretation criteria and validation of interreader reliability, reproducibility, and performance
    Journal Article

    Wray, R.; Mauguen, A.; Michaud, L.; Leithner, D.; Yeh, R.; Riaz, N.; Mirtcheva, R.; Sherman, E.; Wong, R.; Humm, J.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Wu, A. J. C.; Trivedi, N.; Maron, S. B.; Joshi, S. S.; Ilson, D. H.; Janjigian, Y. Y.; Shcherba, M.; Li, J.; Tang, L. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma
    Journal Article

    Lochrin, S. E.; Cugliari, M. K.; Yeh, R.; Shoushtari, A. N.
    Melanoma Research (2024)

    Fulltext@MSK | Save
  • Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
    Journal Article

    Friedman, J. S.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Dogan, A.; Pulitzer, M.; Busam, K. J.; Francis, J. H.; Rampal, R. K.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Hepatic PSMA-avid postradiation inflammation
    Miscellaneous

    Silveira, P.; Razmaria, A.; Yeh, R.
    Clinical Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Three-dimensional margin as a predictor of local tumor progression after microwave ablation: Intraprocedural versus 4–8-week postablation assessment
    Journal Article

    Zirakchian Zadeh, M.; Sotirchos, V. S.; Kirov, A.; Lafontaine, D.; Gönen, M.; Yeh, R.; Kunin, H.; Petre, E. N.; Kitsel, Y.; Elsayed, M.; more...
    Journal of Vascular and Interventional Radiology (2024)

    Fulltext@MSK | Save
  • First-in-human evaluation of site-specifically labeled (89)Zr-pertuzumab in patients with HER2-positive breast cancer
    Journal Article

    Yeh, R.; O'Donoghue, J. A.; Jayaprakasam, V. S.; Mauguen, A.; Min, R.; Park, S.; Brockway, J. P.; Bromberg, J. F.; Zhi, W. I.; Robson, M. E.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save